Browsing Tag
EGFR-Mutated NSCLC
3 posts
Can J&J’s five-minute NSCLC injection disrupt the EGFR frontline market long ruled by osimertinib?
Johnson & Johnson’s five-minute NSCLC injection RYBREVANT FASPRO wins FDA approval. Learn how this subcutaneous delivery could reshape EGFR frontline therapy.
AstraZeneca’s Tagrisso redefines survival bar in advanced EGFR-mutant NSCLC
AstraZeneca’s Tagrisso combo extends survival to nearly 4 years in advanced EGFR-mutated lung cancer. Find out what this means for treatment norms.
Johnson & Johnson’s RYBREVANT and LAZCLUZE show unprecedented survival advantage in lung cancer trial
Johnson & Johnson has revealed transformative results from the Phase 3 MARIPOSA clinical trial, positioning the combination of…